Unknown

Dataset Information

0

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.


ABSTRACT: Objectives:Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). We evaluated patient-reported outcomes (PROs) in patients with PsA refractory to ?1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR) and tumour necrosis factor inhibitor-naïve in a 12-month, phase III randomised controlled trial (OPAL Broaden [NCT01877668]). Methods:Patients (N=422) received tofacitinib 5 mg or 10 mg twice daily, adalimumab 40 mg subcutaneously every 2 weeks or placebo advancing to tofacitinib 5 mg or 10 mg twice daily at month 3. Least squares mean changes from baseline and percentages of patients reporting improvements ?minimum clinically important differences (MCID); and scores ?normative values in: Patient Global Assessment of disease activity (PtGA), Pain, Patient Global Joint and Skin Assessment (PGJS), Short Form-36 Health Survey version 2 (SF-36v2), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue), EuroQol 5-Dimensions-3-level questionnaire (EQ-5D-3L) and Ankylosing Spondylitis Quality of Life (ASQoL) were determined. Nominal p values were cited without multiple comparison adjustments. Results:At month 3, PtGA, Pain, PGJS, FACIT-Fatigue, EQ-5D-3L, ASQoL and SF-36v2 Physical Component Summary (PCS), physical functioning (PF), bodily pain (BP) and vitality domain scores exceeded placebo with both tofacitinib doses (p?0.05); SF-36v2 social functioning with 5 mg twice daily (p?0.05). Percentages reporting improvements ?MCID in PtGA, Pain, PGJS, FACIT-Fatigue, ASQoL and SF-36v2 PCS, PF, BP and general health scores exceeded placebo with both tofacitinib doses (p?0.05) and were similar with adalimumab. Conclusion:csDMARD-IR patients with active PsA reported statistically and clinically meaningful improvements in PROs with tofacitinib compared with placebo at Month 3.

SUBMITTER: Strand V 

PROVIDER: S-EPMC6340575 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.

Strand Vibeke V   de Vlam Kurt K   Covarrubias-Cobos Jose A JA   Mease Philip J PJ   Gladman Dafna D DD   Graham Daniela D   Wang Cunshan C   Cappelleri Joseph C JC   Hendrikx Thijs T   Hsu Ming-Ann MA  

RMD open 20190111 1


<h4>Objectives</h4>Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). We evaluated patient-reported outcomes (PROs) in patients with PsA refractory to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR) and tumour necrosis factor inhibitor-naïve in a 12-month, phase III randomised controlled trial (OPAL Broaden [NCT01877668]).<h4>Methods</h4>Patients (N=422) received tofacitinib 5 mg or 10 mg twice daily, adalimumab 40 mg subcutaneou  ...[more]

Similar Datasets

| S-EPMC4941182 | biostudies-literature
| S-EPMC8572272 | biostudies-literature
| S-EPMC7494680 | biostudies-literature
| S-EPMC5817244 | biostudies-literature
| S-EPMC6902348 | biostudies-literature
| S-EPMC5413813 | biostudies-literature
| S-EPMC6340607 | biostudies-literature
| S-EPMC6334904 | biostudies-literature
| S-EPMC8826651 | biostudies-literature
| S-EPMC6135452 | biostudies-other